Nascent Biotech Valuation
| NBIO Stock | USD 0 0 28.57% |
Nascent Biotech seems to be undervalued based on Macroaxis valuation methodology. Our model forecasts the value of Nascent Biotech from analyzing the firm fundamentals such as Shares Outstanding of 119.56 M, return on asset of -0.88, and Operating Margin of (0.92) % as well as examining its technical indicators and probability of bankruptcy. . In general, most investors recommend obtaining undervalued stocks and abandoning overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Undervalued
Today
Please note that Nascent Biotech's price fluctuation is out of control at this time. Calculation of the real value of Nascent Biotech is based on 3 months time horizon. Increasing Nascent Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Nascent otc stock is determined by what a typical buyer is willing to pay for full or partial control of Nascent Biotech. Since Nascent Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nascent OTC Stock. However, Nascent Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0045 | Real 0.0115 | Hype 0.004155 | Naive 0.004719 |
The intrinsic value of Nascent Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nascent Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nascent Biotech helps investors to forecast how Nascent otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nascent Biotech more accurately as focusing exclusively on Nascent Biotech's fundamentals will not take into account other important factors: Nascent Biotech Total Value Analysis
Nascent Biotech is now forecasted to have valuation of 21.83 M with market capitalization of 10.76 M, debt of 64.89 K, and cash on hands of 145.57 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nascent Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
21.83 M | 10.76 M | 64.89 K | 145.57 K |
Nascent Biotech Investor Information
About 32.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.0. Nascent Biotech had not issued any dividends in recent years. Nascent Biotech is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Nascent Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nascent Biotech has an asset utilization ratio of 948.64 percent. This suggests that the OTC Stock is making $9.49 for each dollar of assets. An increasing asset utilization means that Nascent Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Nascent Biotech Ownership Allocation
Nascent Biotech maintains a total of 119.56 Million outstanding shares. Nascent Biotech holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nascent Biotech Profitability Analysis
The company reported the previous year's revenue of 1000 K. Net Loss for the year was (470.39 K) with profit before overhead, payroll, taxes, and interest of 1000 K.About Nascent Biotech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Nascent Biotech. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Nascent Biotech based exclusively on its fundamental and basic technical indicators. By analyzing Nascent Biotech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Nascent Biotech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nascent Biotech. We calculate exposure to Nascent Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nascent Biotech's related companies.Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Nascent Biotech's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Nascent Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Nascent Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Nascent Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Nascent Biotech's revenue streams: Identify Nascent Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Nascent Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Nascent Biotech's growth potential: Evaluate Nascent Biotech's management, business model, and growth potential.
- Determine Nascent Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Nascent Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Nascent Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 111.3 M | |
| Retained Earnings | -18.8 M |
Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.